This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roper Technologies (ROP) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Roper Technologies (ROP) delivered earnings and revenue surprises of 8.43% and 1.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Roper (ROP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Roper's (ROP) first-quarter 2021 earnings are expected to have benefited from a solid demand environment and strong application software segment, driven by an effective capital deployment strategy.
Roper (ROP) Displays Bright Prospects, Headwinds Persist
by Zacks Equity Research
Roper (ROP) is likely to benefit from strength across its businesses, acquired assets and shareholder-friendly policies. However, the high debt level poses a concern.
Roper Technologies (ROP) Down 10.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Roper Technologies (ROP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roper (ROP) Earnings Surpass Estimates in Q4, Sales Miss
by Zacks Equity Research
Roper (ROP) Q4 earnings increases year over year on the back of sales generation. It provides impressive earnings projections for 2021 compared with the previous year.
Roper Technologies (ROP) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Roper Technologies (ROP) delivered earnings and revenue surprises of 2.01% and -1.07%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Roper (ROP) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Roper's (ROP) fourth-quarter 2020 earnings are likely to have gained from strong network software and medical products. Soft upstream oil and gas businesses might have marred its performance.
Roper Technologies (ROP) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Roper Technologies (ROP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roper (ROP) Displays Solid Prospects Amid Pandemic Scare
by Zacks Equity Research
Roper (ROP) is likely to gain from strength across its network software businesses, acquired assets and shareholder friendly policies. However, the coronavirus outbreak-led woes remain a concern.
The Zacks Analyst Blog Highlights: Motorola, NIKE and Roper
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Motorola, NIKE and Roper
3 Diverse Stocks That Hiked Dividend Despite Coronavirus Woes
by Supriyo Bose
A handful of stocks has chosen to swim against the coronavirus tide and continued rewarding shareholders with dividend hikes.
Roper (ROP) Announces 10% Hike in Quarterly Dividend Rate
by Zacks Equity Research
Roper (ROP) to reward shareholders with a 10% hike in the quarterly dividend rate. This reflects its strong cash position.
Top Analyst Reports for AbbVie, Square & Honda Motor
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Square, Inc. (SQ) and Honda Motor Co., Ltd. (HMC).
Roper Technologies (ROP) Q3 Earnings, Revenues Top Estimates
by Zacks Equity Research
Roper Technologies' (ROP) third-quarter 2020 net revenues increase 0.9% year over year on solid performance across its Application Software, and Network Software & Systems segments.
Roper Technologies (ROP) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Roper Technologies (ROP) delivered earnings and revenue surprises of 5.32% and 1.02%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Roper (ROP) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Roper's (ROP) third-quarter 2020 earnings are likely to have gained from strong network software and medical products. Weak upstream oil and gas businesses are expected to have hurt results.
Roper Technologies (ROP) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Roper Technologies (ROP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Middleby Stock Up 26.4% in 3 Months: What's Driving it?
by Zacks Equity Research
Middleby (MIDD) stands to benefit from a strong product portfolio, improving order trends, solid backlog and acquisitions. However, its debt level remains high.
Tetra Tech Secures $24M Single-Award Contract From USAID
by Zacks Equity Research
Tetra Tech's (TTEK) contract with USAID will help the latter in executing the Regional Water and Vulnerable Environment Activity in Central Asia.
Forget Applied Industrial, Buy These 3 Manufacturing Stocks
by Avisekh Bhattacharjee
Applied Industrial (AIT) is facing weakness in its end markets along with high debt level & forex woes. So, we present 3 industrial manufacturing stocks that are likely to offer good returns.
Flowserve Reshapes Debt With Senior Notes Issue & Redemption
by Zacks Equity Research
Flowserve (FLS) issues senior notes worth $500 million and uses proceeds to redeem Euro-denominated senior notes. These actions are likely to help in restructuring the company's debt profile.
5 Top Dividend Aristocrats to Fend Off Market Volatility
by Tirthankar Chakraborty
With things not looking up for the stock market this September, it's wise to bet on dividend aristocrats for their risk-adjusted returns.
Nordson Arm Unveils Optimum Class VI Dispensing Components
by Zacks Equity Research
Nordson's (NDSN) Optimum Class VI fluid dispensing components help manufacturers in the medical industry to simplify process validation.
Flowserve Offers Senior Notes, To Use Funds for Note Buybacks
by Zacks Equity Research
Flowserve (FLS) prices senior notes offerings worth $500 million and commences tender offer for Euro-denominated senior notes.
Colfax's Products & Cost-Saving Actions to Aid Amid Pandemic
by Zacks Equity Research
Colfax's (CFX) focus on innovation and product launches along with cost-saving measures might aid performances in the quarters ahead. Adversities caused by the pandemic and high debts are concerning.